Andrew Haydon

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.5K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Jeanne Tie, Yuxuan Wang, Cristian Tomasetti et al. · Science Translational Medicine · 2016 · 1.5K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Investigation of the Safety of Irreversible Electroporation in Humans

Kenneth R. Thomson, Wa Cheung, Samantha Ellis et al. · Journal of Vascular and Interventional Radiology · 2011 · 458 citations

Engineering, Biomedical Engineering, Electrochemistry +3

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank et al. · JAMA Oncology · 2020 · 436 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17